• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

    4/11/25 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email

    Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease.

    Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places significant financial strain on patients and their families. Amneal's donations will be directed toward programs that offer funding support for out-of-pocket costs—including copayments, coinsurance, and deductibles—for FDA-approved Parkinson's medications.

    "Parkinson's patients face numerous daily challenges, and access to medication should not be one of them," said Joe Renda, Senior Vice President, Chief Commercial Officer – Specialty at Amneal Pharmaceuticals. "During Parkinson's Awareness Month, we honor those living with this disease by taking action. We are proud to support organizations that are breaking down financial barriers and helping individuals receive the treatment they need to live fuller, more empowered lives. Together with our partners, we aim to foster hope, raise awareness, and improve outcomes for patients and their families."

    Patient assistance foundations have a long-standing impact in alleviating the financial burden of chronic disease. Through this initiative, Amneal is reinforcing its commitment to partnering with the Parkinson's community and supporting programs that make a direct, positive impact on patient care.

    Amneal encourages everyone to join in recognizing Parkinson's Awareness Month and to support ongoing efforts to advance care, raise awareness, and accelerate progress toward a cure.

    About Amneal

    Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered in Bridgewater, NJ, is a global biopharmaceutical company. We make healthy possible through the development, manufacturing, and distribution of a diverse portfolio of over 280 pharmaceuticals, primarily within the United States. In its Affordable Medicines segment, the Company is expanding across a broad range of complex product categories and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more information, please visit www.amneal.com and follow us on LinkedIn.

    Cautionary Statement on Forward-Looking Statements

    Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; and statements regarding our positioning, including our ability to drive sustainable long-term growth, and other non-historical statements. Words such as "plans," "expects," "will," "anticipates," "estimates," and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's filings with the Securities and Exchange Commission, including under Item 1A, "Risk Factors" in the Company's most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250411746912/en/

    Investor Contact

    Anthony DiMeo

    VP, Investor Relations

    [email protected]

    Media Contact

    Randi Kahn

    SVP, Corporate Affairs, Syneos Health

    [email protected]

    Get the next $AMRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMRX

    DatePrice TargetRatingAnalyst
    6/6/2025$12.00Buy
    Goldman
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $AMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

      Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. The randomized, double-blind, multicenter study was conducted by Kashiv to assess the efficacy, safety, and immunogenicity of ADL-018 compare

      6/25/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension

      Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025 BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") today announced the U.S. Food and Drug Administration (FDA) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®. Pred Forte and its design are trademarks of Allergan, Inc., an AbbVie company. Launch of this product is planned for the third quarter of 2025. Prednisolone acetate ophthalmic suspension, USP 1% is a sterile, topical anti-inflammatory agent for ophthalmic use and is indicated for treating steroid-respo

      6/12/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal to Participate at Upcoming Investor Conferences in June

      BRIDGEWATER, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) will participate in two upcoming investor conferences: Jefferies Global Healthcare Conference on June 5, 2025, with company presentation at 9:20 AM ET, and Goldman Sachs Global Healthcare Conference on June 10, 2025, with fireside chat at 10:40 AM ET. Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Executive Vice President and Chief Financial Officer, will participate in both conferences. A live webcast will be accessible at https://investors.amneal.com with replays available following both events. About AmnealAmneal Pharmaceuticals, Inc. (NASDAQ:AMRX), headquartered

      5/29/25 4:05:00 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care